Reporter virus particles (RVPs) package the capsid-preMembrane-envelope (C-prM-E) gene construct of West Nile Virus (WNV) (GenBank: DQ211652.1, NY99 strain) and a Renilla luciferase reporter. As the wild typed WNV is handled under BSL-2 precautions, this WNV RVP can be handled using BSL-2 containment practices.

• Applications:
• Anti-West Nile Virus (WNV) neutralizing antibody screening at high throughput
• Anti-West Nile Virus (WNV) drug screening at high throughput
• West Nile Virus (WNV) vaccine efficacy evaluation at high throughput
• West Nile Virus (WNV) pseudovirus transduction of target cells for viral entry, receptor recognition, cellular tropism and functional studies, such as ADCC or ADE analysis

Description: Infection of cells with this RVP carrying Renilla luciferase reporter results in high level Renilla luciferase activity. See our titration result showing that the starting 2-fold diluted RVP-infected target cells (Vero) generates signal ~ 10,000-fold higher than uninfected control (cell alone as background in blue). We also evaluated the neutralizing activity of one known neutralizing monoclonal antibody- E60 that binds to domain DI/DII region of the viral envelope protein.

Biosafety level: Handle it in biosafety cabinet in BSL-2. Contacted tips and tubes should be decontaminated by 10% disinfecting bleach.

Use protocol: A complete protocol is supplied with the shipping of product. Briefly, incubate 50 μl diluted virus with your sample in each well of 96-well plate with at least one duplicate for 30 to 60 min at 37 °C. Then add 50 μl target cells (Vero or others expressing receptor). Read Renilla luciferase signal next day.